Developer docs
API playgroundTry for free, no card

Search company profiles

NanoViricides

Full company profile

uuid0003ph4

Namestring
NanoViricides
Legal namestring
NanoViricides, Inc.
Company typeenum
Public
Founded yearint
2005
Descriptiontext

NanoViricides, Inc. is a clinical-stage nano-biopharmaceutical company founded in 2005 and listed on NYSE American under ticker NNVC. The company is developing a pipeline of antiviral therapeutics built on a proprietary host-mimetic nanomedicine platform licensed from TheraCour Pharma. The core technology uses polymeric micelles that mimic heparan sulfate proteoglycan (HSPG) receptors on host cell surfaces; because 90–95% of known human pathogenic viruses require HSPG for cell entry, the platform claims viruses cannot escape its mechanism through mutation. The lead drug candidate, NV-387, is formulated as an oral gummy and has demonstrated broad-spectrum activity in animal models against RSV, COVID-19, influenza, mpox, smallpox, measles, and ebola. NV-387 received FDA Orphan Drug Designation for measles in April 2026 and is in Phase II trials for mpox (Clade I) and Bundibugyo ebola in the Democratic Republic of Congo, supported by CRO Om Sai Clinical Research.

The company operates with 1–10 employees from a headquarters and cGMP-capable manufacturing facility in Shelton, Connecticut. Additional pipeline assets include NV-HHV-1 for shingles, NV-CoV-2 and NV-CoV-2-R (the latter encapsulating remdesivir) for COVID-19, HerpeCide for herpes viruses, FluCide for influenza, and HIVCide for HIV. Business model is pre-revenue: NanoViricides funds operations through periodic registered direct equity offerings (e.g., $6M in November 2025 and $2M in May 2026 with D. Boral Capital as placement agent) plus a $3M unused credit line from founder Dr. Anil R. Diwan. Anticipated revenue streams post-approval include US Strategic National Stockpile contracts for pandemic preparedness (modeled on TPOXX/TEMBEXA deals worth hundreds of millions of dollars), a potential Priority Review Voucher (~$150–200M) tied to a measles Rare Pediatric Disease Designation, and orphan drug market exclusivity. The company has disclosed that cash on hand as of March 31, 2026 is insufficient to fund operations beyond mid-February 2026 without additional financing.

Short descriptiontext

NanoViricides is a clinical-stage nano-biopharmaceutical company developing broad-spectrum antiviral therapeutics based on a proprietary host-mimetic polymeric micelle platform, with lead candidate NV-387 in Phase II trials for mpox and ebola and FDA Orphan Drug Designation for measles.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersWest Haven, United States
HQ citystring
West Haven
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antiviral therapeutics, nanomedicine platform, viral infection treatment, clinical-stage biopharmaceutical, host-mimetic drug delivery
Industry2 codes
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAAAG
Nanobodies & Alternative Antibody Scaffolds
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code4 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Nanotechnology541713
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical and Medicine Manufacturing32541
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
  • Medicinal Chemicals & Botanical Products2833
Product category
Antiviral Pharmaceuticals
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model5 records
1Pharmaceutical Drug Sales
TypeOne Time License
Description

Revenue from commercial sales of approved antiviral drugs following successful clinical development and regulatory approval. Target markets include RSV, influenza, COVID-19, mpox, smallpox, and measles treatments with estimated market sizes exceeding $25 billion.

nanoviricides.com
2Government SNS Stockpiling Contracts
TypeOne Time License
Description

US Government Strategic National Stockpile contracts for pandemic preparedness bioterrorism agents. Existing smallpox drugs TPOXX and TEMBEXA represent several hundreds of millions of dollars in potential opportunity for NV-387 if approved.

nanoviricides.com
3Priority Review Voucher (PRV)
TypeLicensing Royalties
Description

Upon FDA approval of NV-387 for Rare Pediatric Disease (measles), company may receive transferable PRV worth estimated $150-200 million that can be sold to other pharmaceutical companies.

stocktitan.net
4Orphan Drug Market Exclusivity
TypeOne Time License
Description

FDA Orphan Drug Designation provides 7 years of market exclusivity upon approval, tax credits for clinical trials, and exemption from certain user fees. Received ODD for measles treatment.

nanoviricides.com
5Non-Dilutive Grant Funding
TypeLicensing Royalties
Description

Pursuing US government grants for development of pandemic preparedness countermeasures, particularly for measles treatment development in the USA.

nanoviricides.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Infrastructure, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 6 records shown
1NV-387
Description

Broad-spectrum antiviral drug candidate targeting RSV, COVID-19, Influenza, MPox, Smallpox, and Measles

nanoviricides.com
+5 more records
Core offering1 text field

NanoViricides is a clinical-stage nano-biopharmaceutical company developing broad-spectrum antiviral therapeutics using its proprietary nanoviricide platform technology. The platform uses polymeric micelle-based nanomedicines that mimic host cell receptors (heparan sulfate proteoglycans) to bind, engulf, and destroy viruses. Its lead drug candidate NV-387, formulated as oral gummies, is in Phase II clinical trials targeting mpox, ebola, measles, RSV, COVID-19, and influenza.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 170% survival improvement over untreated animals for NV-387 IV vs 40% for remdesivir in lethal COVID-19 animal model
+4 more records
Product overview1 text field

NanoViricides is a clinical-stage nano-biopharmaceutical company developing antiviral drugs using its proprietary nanoviricide® platform technology. The lead product is NV-387, a broad-spectrum antiviral drug in Phase II clinical trials for MPox and Ebola treatment, with Orphan Drug Designation for Measles. The company also has NV-HHV-1 for Shingles, NV-CoV-2 and NV-CoV-2-R for COVID-19, and earlier-stage candidates for HIV, Influenza (FluCide), Dengue, Rabies, and Ebola/Marburg. The platform technology mimics host cell receptors that viruses bind to, creating drugs that viruses cannot escape through mutation.

Product and service7 records
1NV-387 Oral Gummies
CategoryAntiviral Drug Candidate
Description

Broad-spectrum antiviral drug candidate that mimics host cell features (heparan sulfate proteoglycan) to bind and destroy viruses. Effective against RSV, COVID-19, Influenza, MPox, Smallpox, Measles, and Ebola. Administered as oral gummies. In Phase II clinical trials.

2NV-HHV-1
3NV-CoV-2
CategoryAntiviral Drug Candidate
Description

Nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. Based on the NV-387 platform technology.

4NV-CoV-2-R
CategoryAntiviral Drug Candidate
Description

COVID-19 drug candidate composed of NV-387 with remdesivir encapsulated within its polymeric micelles. The company believes this may be an approvable drug if safety is comparable to remdesivir.

5HerpeCide Program (NV-HHV-101)
CategoryAntiviral Drug Candidate
Description

Broad-spectrum drug program targeting herpes viruses including HSV-1 (cold sores), HSV-2 (genital herpes), and herpes keratitis (eye drops). Topical treatment advancing toward IND filing.

6FluCide Program
CategoryAntiviral Drug Candidate
Description

Drug candidates against all influenzas including H1N1 swine flu and H5N1 bird flu at different preclinical stages.

7HIVCide
CategoryAntiviral Drug Candidate
Description

Pan-HIV drug candidate based on host-cell-mimetic nanoviricide technology, potentially for functional cure.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2025-12-01
Description

Regulatory consulting firm founded by former FDA Office of Orphan Products Development Director Dr. Timothy Cote engaged to develop orphan drug strategy for NV-387 targeting Mpox, Smallpox, and Measles. Master Services Agreement signed December 1, 2025 for preparing and prosecuting orphan drug designation applications with US FDA.

2TheraCour Pharma, Inc.
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

Licensing partner holding intellectual property for nanoviricide technology. NanoViricides has Memorandum of Understanding with TheraCour for development of drugs based on these technologies for all antiviral infections. The company holds broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour.

nanoviricides.com
3Om Sai Clinical Research Private Limited
Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

CRO retained for Phase II clinical trials in DRC. Instrumental in successful submission of proposal to Pillar Committee for Phase II Ebola clinical trial. Conducting site preparations and staff training for mpox trial in DRC with associates in country.

financialcontent.com
4AllExcel, Inc.
Strategic tierCoreTypeTechnology or Integration
Description

Technology licensor for TheraCour nanomedicine platform technology. TheraCour licenses the TheraCour technology from AllExcel. NanoViricides holds exclusive perpetual license to this technology for specific antiviral applications.

nanoviricides.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Remdesivir developer referenced in context of NV-CoV-2-R drug candidate that encapsulates remdesivir within nanoviricide polymeric micelles. Company states that since remdesivir is already FDA approved, their drug candidate encapsulating remdesivir is likely to be approvable if safety is comparable. Developed independently by NanoViricides.

Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Contract research organization engaged for IND-enabling Safety/Toxicology studies for shingles drug candidate NV-HHV-101 beginning December 2018. Studies typically last six to nine months.

7Academic and Research Collaborators
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Multiple collaborations at leading academic, private, and federal laboratories performing independent nanoviricide testing against various viral targets. Core IP studies performed internally while biological effectiveness and safety studies performed by external collaborators.

nanoviricides.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

SIGA Technologies develops TPOXX (tecovirimat), the leading FDA-approved smallpox antiviral that NanoViricides explicitly benchmarks against for NV-387 in orthopoxvirus indications. Both companies target US Strategic National Stockpile contracts for pandemic preparedness and bioterrorism response.

TypeDirect peer
Description

Emergent BioSolutions manufactures TEMBEXA (brincidofovir), another US-government stockpiled smallpox antiviral referenced by NanoViricides as a comparable commercial opportunity. Both companies compete in the pandemic preparedness and biodefense procurement space.

TypeBroad incumbent
Description

Gilead developed remdesivir, the COVID-19 antiviral that NanoViricides' NV-CoV-2-R candidate aims to improve upon by encapsulating remdesivir in polymeric micelles. Gilead's established antiviral franchise, global commercial infrastructure, and pipeline of nucleotide analog drugs make it both a benchmark and a competitive threat.

TypeDirect peer
Description

Vir Biotechnology develops monoclonal antibody-based antivirals for influenza, COVID-19, RSV, and hepatitis B, directly competing in the same broad-spectrum antiviral market NanoViricides targets. Vir's antibody platform represents an alternative modality to NanoViricides' host-mimetic nanomedicine approach.

TypeDirect peer
Description

Cocrystal Pharma is a clinical-stage antiviral biotech developing oral broad-spectrum antiviral candidates for influenza, COVID-19, and norovirus. Like NanoViricides, it is a small public company pursuing innovative antiviral mechanisms without approved products.

TypeDirect peer
Description

Atea Pharmaceuticals develops oral direct-acting antivirals, most notably for hepatitis C and COVID-19 (in partnership with Roche). The company represents a comparable small-cap clinical-stage antiviral biotech pursuing oral formulations to compete in similar indications.

TypeEmerging player
Description

Arbutus Biopharma develops antiviral therapies targeting hepatitis B and coronaviruses using novel mechanisms. As a clinical-stage antiviral biotech, it parallels NanoViricides' risk profile and focus on chronic and emerging viral infections.

TypeEmerging player
Description

Inovio Pharmaceuticals develops DNA-based vaccines and antivirals targeting HPV, COVID-19, and other infectious diseases. As a small clinical-stage biotech focused on viral diseases, it shares NanoViricides' profile of pre-revenue operation dependent on capital markets.

TypeDirect peer
Description

BioCryst Pharmaceuticals markets oral antivirals including Rapivab (peramivir) for influenza and is developing BCX-7353 for hereditary angioedema. As a commercial-stage antiviral company, BioCryst represents the trajectory NanoViricides aspires to in respiratory viral infections.

TypeDirect peer
Description

Chimerix develops antivirals including TEMBEXA (acquired from Emergent) and is developing dordaviprone for recurrent gliomas. The company's focus on orthopoxvirus treatments and smallpox preparedness directly overlaps with NanoViricides' mpox/smallpox program.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NanoViricides

Antiviral Pharmaceuticalsnanoviricides.com

NanoViricides is a clinical-stage nano-biopharmaceutical company developing broad-spectrum antiviral therapeutics based on a proprietary host-mimetic polymeric micelle platform, with lead candidate NV-387 in Phase II trials for mpox and ebola and FDA Orphan Drug Designation for measles.

What NanoViricides does

NanoViricides, Inc. is a clinical-stage nano-biopharmaceutical company founded in 2005 and listed on NYSE American under ticker NNVC. The company is developing a pipeline of antiviral therapeutics built on a proprietary host-mimetic nanomedicine platform licensed from TheraCour Pharma. The core technology uses polymeric micelles that mimic heparan sulfate proteoglycan (HSPG) receptors on host cell surfaces; because 90–95% of known human pathogenic viruses require HSPG for cell entry, the platform claims viruses cannot escape its mechanism through mutation. The lead drug candidate, NV-387, is formulated as an oral gummy and has demonstrated broad-spectrum activity in animal models against RSV, COVID-19, influenza, mpox, smallpox, measles, and ebola. NV-387 received FDA Orphan Drug Designation for measles in April 2026 and is in Phase II trials for mpox (Clade I) and Bundibugyo ebola in the Democratic Republic of Congo, supported by CRO Om Sai Clinical Research.

The company operates with 1–10 employees from a headquarters and cGMP-capable manufacturing facility in Shelton, Connecticut. Additional pipeline assets include NV-HHV-1 for shingles, NV-CoV-2 and NV-CoV-2-R (the latter encapsulating remdesivir) for COVID-19, HerpeCide for herpes viruses, FluCide for influenza, and HIVCide for HIV. Business model is pre-revenue: NanoViricides funds operations through periodic registered direct equity offerings (e.g., $6M in November 2025 and $2M in May 2026 with D. Boral Capital as placement agent) plus a $3M unused credit line from founder Dr. Anil R. Diwan. Anticipated revenue streams post-approval include US Strategic National Stockpile contracts for pandemic preparedness (modeled on TPOXX/TEMBEXA deals worth hundreds of millions of dollars), a potential Priority Review Voucher (~$150–200M) tied to a measles Rare Pediatric Disease Designation, and orphan drug market exclusivity. The company has disclosed that cash on hand as of March 31, 2026 is insufficient to fund operations beyond mid-February 2026 without additional financing.

NanoViricides firmographics

Firmographics
Name
NanoViricides
Legal name
NanoViricides, Inc.
Website
https://nanoviricides.com
Company type
Public
Founded year
2005
Operating status
Operating
Headcount range
1–10 employees
Short description
NanoViricides is a clinical-stage nano-biopharmaceutical company developing broad-spectrum antiviral therapeutics based on a proprietary host-mimetic polymeric micelle platform, with lead candidate NV-387 in Phase II trials for mpox and ebola and FDA Orphan Drug Designation for measles.
Ownership category
akta.pro rank

NanoViricides industry classification

Industry
Product category
Antiviral Pharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Nanotechnology (541713), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (32541)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAAAG
Nanobodies & Alternative Antibody Scaffolds
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Antiviral therapeutics
  • Nanomedicine platform
  • Viral infection treatment
  • Clinical-stage biopharmaceutical
  • Host-mimetic drug delivery

Where NanoViricides is headquartered

Location

Headquarters

HQ city
West Haven
HQ country
United States
HQ region
North America

Offices2 records

Markets served

NanoViricides business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Infrastructure, Operations

Revenue model

  1. Pharmaceutical Drug Sales: Revenue from commercial sales of approved antiviral drugs following successful clinical development and regulatory approval. Target markets include RSV, influenza, COVID-19, mpox, smallpox, and measles treatments with estimated market sizes exceeding $25 billion.
  2. Government SNS Stockpiling Contracts: US Government Strategic National Stockpile contracts for pandemic preparedness bioterrorism agents. Existing smallpox drugs TPOXX and TEMBEXA represent several hundreds of millions of dollars in potential opportunity for NV-387 if approved.
  3. Priority Review Voucher (PRV): Upon FDA approval of NV-387 for Rare Pediatric Disease (measles), company may receive transferable PRV worth estimated $150-200 million that can be sold to other pharmaceutical companies.
  4. Orphan Drug Market Exclusivity: FDA Orphan Drug Designation provides 7 years of market exclusivity upon approval, tax credits for clinical trials, and exemption from certain user fees. Received ODD for measles treatment.
  5. Non-Dilutive Grant Funding: Pursuing US government grants for development of pandemic preparedness countermeasures, particularly for measles treatment development in the USA.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels8 records

NanoViricides product offering

Product offering

Core offering

NanoViricides is a clinical-stage nano-biopharmaceutical company developing broad-spectrum antiviral therapeutics using its proprietary nanoviricide platform technology. The platform uses polymeric micelle-based nanomedicines that mimic host cell receptors (heparan sulfate proteoglycans) to bind, engulf, and destroy viruses. Its lead drug candidate NV-387, formulated as oral gummies, is in Phase II clinical trials targeting mpox, ebola, measles, RSV, COVID-19, and influenza.

Product overview

NanoViricides is a clinical-stage nano-biopharmaceutical company developing antiviral drugs using its proprietary nanoviricide® platform technology. The lead product is NV-387, a broad-spectrum antiviral drug in Phase II clinical trials for MPox and Ebola treatment, with Orphan Drug Designation for Measles. The company also has NV-HHV-1 for Shingles, NV-CoV-2 and NV-CoV-2-R for COVID-19, and earlier-stage candidates for HIV, Influenza (FluCide), Dengue, Rabies, and Ebola/Marburg. The platform technology mimics host cell receptors that viruses bind to, creating drugs that viruses cannot escape through mutation.

Differentiator

Problem solved

Functional benefit

Brands

  • NV-387: Broad-spectrum antiviral drug candidate targeting RSV, COVID-19, Influenza, MPox, Smallpox, and Measles
  • NV-HHV-1
  • NV-CoV-2
  • NV-CoV-2-R
  • HerpeCide
  • FluCide

Products and services

  • NV-387 Oral Gummies Broad-spectrum antiviral drug candidate that mimics host cell features (heparan sulfate proteoglycan) to bind and destroy viruses. Effective against RSV, COVID-19, Influenza, MPox, Smallpox, Measles, and Ebola. Administered as oral gummies. In Phase II clinical trials.
  • NV-HHV-1
  • NV-CoV-2 Nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. Based on the NV-387 platform technology.
  • NV-CoV-2-R COVID-19 drug candidate composed of NV-387 with remdesivir encapsulated within its polymeric micelles. The company believes this may be an approvable drug if safety is comparable to remdesivir.
  • HerpeCide Program (NV-HHV-101) Broad-spectrum drug program targeting herpes viruses including HSV-1 (cold sores), HSV-2 (genital herpes), and herpes keratitis (eye drops). Topical treatment advancing toward IND filing.
  • FluCide Program Drug candidates against all influenzas including H1N1 swine flu and H5N1 bird flu at different preclinical stages.
  • HIVCide Pan-HIV drug candidate based on host-cell-mimetic nanoviricide technology, potentially for functional cure.

Quantifiable outcome

  • 170% survival improvement over untreated animals for NV-387 IV vs 40% for remdesivir in lethal COVID-19 animal model
  • +4 more outcomes

Companies that use NanoViricides

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles3 records

NanoViricides technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

NanoViricides partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • Only Orphans Cote, LLCcoreImplementation/ SI/ Consulting Partner · 1 December 2025Regulatory consulting firm founded by former FDA Office of Orphan Products Development Director Dr. Timothy Cote engaged to develop orphan drug strategy for NV-387 targeting Mpox, Smallpox, and Measles. Master Services Agreement signed December 1, 2025 for preparing and prosecuting orphan drug designation applications with US FDA.
  • TheraCour Pharma, Inc.coreOEM/ Whitelabel/ Licensing PartnerLicensing partner holding intellectual property for nanoviricide technology. NanoViricides has Memorandum of Understanding with TheraCour for development of drugs based on these technologies for all antiviral infections. The company holds broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour.
  • Om Sai Clinical Research Private LimitedcoreImplementation/ SI/ Consulting PartnerCRO retained for Phase II clinical trials in DRC. Instrumental in successful submission of proposal to Pillar Committee for Phase II Ebola clinical trial. Conducting site preparations and staff training for mpox trial in DRC with associates in country.
  • AllExcel, Inc.coreTechnology or IntegrationTechnology licensor for TheraCour nanomedicine platform technology. TheraCour licenses the TheraCour technology from AllExcel. NanoViricides holds exclusive perpetual license to this technology for specific antiviral applications.
  • Gilead SciencesminorStrategic or Co-development PartnerRemdesivir developer referenced in context of NV-CoV-2-R drug candidate that encapsulates remdesivir within nanoviricide polymeric micelles. Company states that since remdesivir is already FDA approved, their drug candidate encapsulating remdesivir is likely to be approvable if safety is comparable. Developed independently by NanoViricides.
  • BASi (Bioanalytical Systems, Inc.)minorImplementation/ SI/ Consulting PartnerContract research organization engaged for IND-enabling Safety/Toxicology studies for shingles drug candidate NV-HHV-101 beginning December 2018. Studies typically last six to nine months.
  • Academic and Research CollaboratorsminorStrategic or Co-development PartnerMultiple collaborations at leading academic, private, and federal laboratories performing independent nanoviricide testing against various viral targets. Core IP studies performed internally while biological effectiveness and safety studies performed by external collaborators.

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

NanoViricides competitors and assessment

Company assessment

Direct peers

  • SIGA Technologies: SIGA Technologies develops TPOXX (tecovirimat), the leading FDA-approved smallpox antiviral that NanoViricides explicitly benchmarks against for NV-387 in orthopoxvirus indications. Both companies target US Strategic National Stockpile contracts for pandemic preparedness and bioterrorism response.
  • Emergent BioSolutions: Emergent BioSolutions manufactures TEMBEXA (brincidofovir), another US-government stockpiled smallpox antiviral referenced by NanoViricides as a comparable commercial opportunity. Both companies compete in the pandemic preparedness and biodefense procurement space.
  • Vir Biotechnology: Vir Biotechnology develops monoclonal antibody-based antivirals for influenza, COVID-19, RSV, and hepatitis B, directly competing in the same broad-spectrum antiviral market NanoViricides targets. Vir's antibody platform represents an alternative modality to NanoViricides' host-mimetic nanomedicine approach.
  • Cocrystal Pharma: Cocrystal Pharma is a clinical-stage antiviral biotech developing oral broad-spectrum antiviral candidates for influenza, COVID-19, and norovirus. Like NanoViricides, it is a small public company pursuing innovative antiviral mechanisms without approved products.
  • Atea Pharmaceuticals: Atea Pharmaceuticals develops oral direct-acting antivirals, most notably for hepatitis C and COVID-19 (in partnership with Roche). The company represents a comparable small-cap clinical-stage antiviral biotech pursuing oral formulations to compete in similar indications.
  • BioCryst Pharmaceuticals: BioCryst Pharmaceuticals markets oral antivirals including Rapivab (peramivir) for influenza and is developing BCX-7353 for hereditary angioedema. As a commercial-stage antiviral company, BioCryst represents the trajectory NanoViricides aspires to in respiratory viral infections.
  • Chimerix: Chimerix develops antivirals including TEMBEXA (acquired from Emergent) and is developing dordaviprone for recurrent gliomas. The company's focus on orthopoxvirus treatments and smallpox preparedness directly overlaps with NanoViricides' mpox/smallpox program.

Broad incumbents

  • Gilead Sciences: Gilead developed remdesivir, the COVID-19 antiviral that NanoViricides' NV-CoV-2-R candidate aims to improve upon by encapsulating remdesivir in polymeric micelles. Gilead's established antiviral franchise, global commercial infrastructure, and pipeline of nucleotide analog drugs make it both a benchmark and a competitive threat.

Emerging players

  • Arbutus Biopharma: Arbutus Biopharma develops antiviral therapies targeting hepatitis B and coronaviruses using novel mechanisms. As a clinical-stage antiviral biotech, it parallels NanoViricides' risk profile and focus on chronic and emerging viral infections.
  • Inovio Pharmaceuticals: Inovio Pharmaceuticals develops DNA-based vaccines and antivirals targeting HPV, COVID-19, and other infectious diseases. As a small clinical-stage biotech focused on viral diseases, it shares NanoViricides' profile of pre-revenue operation dependent on capital markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

NanoViricides social profiles

Digital presence

NanoViricides financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NanoViricides leadership team

Management profile

Number of profiles

Profiles7 records

NanoViricides funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NanoViricides M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NanoViricides

What does NanoViricides do?

NanoViricides is a clinical-stage nano-biopharmaceutical company developing broad-spectrum antiviral therapeutics using its proprietary nanoviricide platform technology. The platform uses polymeric micelle-based nanomedicines that mimic host cell receptors (heparan sulfate proteoglycans) to bind, engulf, and destroy viruses. Its lead drug candidate NV-387, formulated as oral gummies, is in Phase II clinical trials targeting mpox, ebola, measles, RSV, COVID-19, and influenza.

Is NanoViricides a public or private company?

NanoViricides is a public company. It is classified as public and is currently operating.

When was NanoViricides founded?

NanoViricides was founded in 2005. It employs 1 to 10 people.

Where is NanoViricides based?

NanoViricides is headquartered in West Haven, United States, in the North America region.

How does NanoViricides make money?

Five revenue lines are on record. Pharmaceutical Drug Sales are the primary driver. The others are government SNS Stockpiling Contracts, priority Review Voucher (PRV), orphan Drug Market Exclusivity and non-Dilutive Grant Funding.

Who are NanoViricides's main competitors?

Direct peers on record are SIGA Technologies, Emergent BioSolutions, Vir Biotechnology, Cocrystal Pharma, Atea Pharmaceuticals, BioCryst Pharmaceuticals and Chimerix. Gilead Sciences is listed as a broad incumbent. Emerging players are Arbutus Biopharma and Inovio Pharmaceuticals.

Does NanoViricides have an API?

No public API is recorded for NanoViricides.

What industry is NanoViricides in?

NanoViricides's product category is Antiviral Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals, with a secondary code of HLAAAAAG, Nanobodies & Alternative Antibody Scaffolds. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooNanoViricides' Revolutionary Broad-Spectrum Drug Candidate NV-387 Has Successfully Demonstrated Excellent Indications for Safety and Toxicology in a Juvenile Mouse Pups Animal Study, Paving the Way for Pediatric Use in Clinical TrialsNanoViricides reported that its broad-spectrum antiviral NV-387 was well-tolerated in a juvenile mouse study, with no adverse effects at the highest dose of 1,230 mg/kg per dose. The results support pediatric use in clinical trials, including for Ebola, Mpox, and Measles, with potential Phase III pediatric cohorts.FinancialContent Business PageNanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical TrialsNanoViricides filed its 2026 annual report with the SEC, detailing Phase II trials for its broad-spectrum antiviral NV-387 against MPox and Ebola. The company also received US FDA orphan drug designations for measles treatment and reported cash of $2.79 million as of June 30, 2026.NewswireNanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical TrialsNanoViricides filed its 2026 annual report with the SEC, detailing Phase II clinical trials for its broad-spectrum antiviral NV-387 against MPox and Ebola. The company also received US FDA orphan drug designations for measles treatment and reported cash of $2.79 million as of June 30, 2026.BioSpaceClinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricidesNanoViricides announced that its Phase II clinical trial of NV-387 oral gummies for Ebola in the DRC began enrolling and dosing patients on September 23, 2026. The trial is a single-arm safety and dose run-in (Phase IIA) followed by a randomized, controlled efficacy evaluation (Phase IIB). The company expects the oral drug to be effective against the Bundibugyo variant, which has a 48% crude fatality rate.NewswirePhase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricidesNanoViricides announced that its Phase II clinical trial of NV-387 for monkeypox treatment has begun in the Democratic Republic of Congo, with first patient enrollment. The trial, led by Prof. Vivi Maketa Tevuzula, will compare the drug to standard of care. The company has applied for FDA orphan drug designation, which could yield tens of millions in benefits.MorningstarPhase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricidesNanoViricides announced that its Phase II clinical trial of NV-387 for monkeypox treatment has begun in the Democratic Republic of Congo, with first patient enrollment. The trial, led by Prof. Vivi Maketa Tevuzula, will compare the oral gummy antiviral to standard of care. The company has applied for US FDA orphan drug designation, which could yield tens of millions in benefits.Simply Wall StThese Biotech Stocks Are Cheap Based On 1 Fundamental MeasureThree biotech stocks—Optimi Health, PMV Pharmaceuticals, and NanoViricides—are highlighted for having P/B ratios below sector norms. Optimi Health reports CA$0.18 million revenue and rising MDMA shipments to Australian clinics, while PMV Pharmaceuticals trades at 1.5x P/B with Phase 2 data, and NanoViricides trades below peers despite no revenue.BioSpaceClinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand in DR CongoNanoViricides registered its Phase II trial of NV-387 oral gummies for Ebola in DRC, with first dosing expected within one to two weeks. The Bundibugyo outbreak has 6,604 cases and 3,175 deaths, a 48% fatality rate, and is the fastest-growing Ebola outbreak.NewswireClinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand in DR CongoNanoViricides registered its Phase II trial of NV-387 oral gummies for Ebola in DRC, with first dosing expected within one to two weeks. The trial targets the Bundibugyo outbreak, which has 6,604 cases and 3,175 deaths as of September 5, 2026.Markets DailyNanoViricides (NYSE:NNVC) Stock Price Down 2.2% – Time to Sell?NanoViricides shares declined 2.2% to $1.31 on Thursday, with trading volume significantly below the daily average. Noble Financial initiated coverage with an "outperform" rating and a $6.00 price target, contributing to an average consensus of "Buy" among analysts. Institutional investors including Susquehanna International Group and State Street Corp have recently increased their holdings in the clinical-stage biotechnology firm.